Boswellia Serrata Extract in Treating Patients with Ductal Breast Carcinoma In Situ or Stage I-III Breast Cancer That Are Undergoing Surgery

Inclusion Criteria

• Histologically confirmed ductal carcinoma in situ (DCIS) or invasive breast cancer (stages I, II, or III) with primary tumor(s) >= 5 mm on mammogram, ultrasound, magnetic resonance imaging (MRI), or physical exam
• Subject must understand risks and benefits of the protocol and be able to give informed consent
• Women of child-bearing potential (WOCBP) must agree to use an approved form of birth control and to have a negative pregnancy test result before registration; WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal; menopause is defined clinically as 12 consecutive months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes; approved forms of birth control: * Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, or transdermal) * Progestogen only hormonal contraception associated with inhibition of ovulation (oral, injectable, or implantable) * Intrauterine device, intrauterine hormone-releasing system * Bilateral tubal occlusion/ligation * Vasectomized partner * Barrier contraception * Sexual abstinence
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (within 14 days prior to registration)
• Platelet count >= 100 x 10^9/L (within 14 days prior to registration)
• Hemoglobin >= 9 g/dL (within 14 days prior to registration)
• Albumin >= 2.5 g/dL (within 14 days prior to registration)
• Bilirubin =< 1.5 x the upper limit of normal (ULN) (within 14 days prior to registration)
• Aspartate aminotransferase (AST), alanine aminotransferase (ALT), =< 3 x ULN (within 14 days prior to registration)
• Serum creatinine =< 1.5 x ULN or creatinine clearance (CrCl) >= 40 mL/min on the basis of measured CrCl from a 24-hour urine collection or Cockcroft-Gault glomerular filtration rate estimation (within 14 days prior to registration)
• Ability and capacity to comply with the study and follow-up procedures
• Subjects must be scheduled for surgery at Medical University of South Carolina (MUSC) no less than 5 days from the planned start of day 1 and no more than 56 days from the planned start of day 1
• For breast cancer patients, at least 6 sections of unstained slides should be obtained; if sufficient slides or tissue is unavailable, the patient will be excluded from the trial

Exclusion Criteria

• Subjects undergoing neoadjuvant chemotherapy or neoadjuvant endocrine therapy
• Subjects with end-stage kidney disease and/or grade II liver dysfunction
• Subject has active or history of deep vein thrombosis (DVT)
• Subject has a history of coagulopathies or hematological disorders
• Subjects who are pregnant or are lactating
• Subjects already taking drugs known to be 5-lipoxygenase inhibitors
• Subjects taking drugs that interact with OATP1B3 (an anion transporter), MRP2 (a multidrug resistant protein), and/or P-glycoprotein (P-Gp)
• Subjects taking anti-coagulants or platelet inhibitors
• Subjects with bowel obstruction
• Subjects undergoing emergency surgery